Jaguar Health Inc. Daily Stock Analysis

Daily Stock Analysis, JAGX, Jaguar Health Inc, priceseries

Jaguar Health Inc. Daily Stock Analysis
Stock Information
Open
0.40
Close
0.38
High
0.40
Low
0.37
Previous Close
0.40
Daily Price Gain
-0.02
YTD High
1.13
YTD High Date
Jan 4, 2022
YTD Low
0.37
YTD Low Date
Mar 7, 2022
YTD Price Change
-0.69
YTD Gain
-64.62%
52 Week High
7.44
52 Week High Date
Mar 8, 2021
52 Week Low
0.37
52 Week Low Date
Mar 7, 2022
52 Week Price Change
-6.13
52 Week Gain
-94.18%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Feb 17. 2017
3024.00
Mar 7. 2017
3367.91
11 Trading Days
11.37%
Link
LONG
Jul 13. 2017
1761.16
Jul 26. 2017
2015.76
9 Trading Days
14.46%
Link
LONG
Nov 13. 2017
670.32
Nov 14. 2017
721.04
1 Trading Days
7.57%
Link
LONG
Jan 16. 2018
441.00
Jan 23. 2018
466.20
5 Trading Days
5.71%
Link
LONG
Feb 2. 2018
466.20
Feb 6. 2018
521.32
2 Trading Days
11.82%
Link
LONG
Jan 2. 2019
56.70
Jan 10. 2019
61.29
6 Trading Days
8.09%
Link
LONG
Mar 27. 2019
59.22
Mar 28. 2019
67.94
1 Trading Days
14.72%
Link
LONG
Nov 11. 2019
2.37
Nov 14. 2019
2.62
3 Trading Days
10.76%
Link
LONG
Dec 31. 2019
2.40
Jan 2. 2020
2.64
1 Trading Days
9.93%
Link
LONG
May 4. 2020
1.39
May 14. 2020
1.56
8 Trading Days
12.44%
Link
LONG
Jun 5. 2020
1.40
Jun 11. 2020
1.48
4 Trading Days
5.45%
Link
LONG
Jul 7. 2020
1.62
Jul 14. 2020
1.74
5 Trading Days
7.18%
Link
LONG
Dec 22. 2020
1.19
Jan 20. 2021
9.04
18 Trading Days
661.27%
Link
LONG
May 21. 2021
3.99
Jun 14. 2021
5.53
15 Trading Days
38.52%
Link
Company Information
Stock Symbol
JAGX
Exchange
NasdaqCM
Company URL
http://www.jaguaranimalhealth.com
Company Phone
415-896-5081
CEO
Lisa A. Conte
Headquarters
California
Business Address
201 MISSION STREET, SUITE 2375, SAN FRANCISCO, CA 94105
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001585608
About

Jaguar Animal Health, Inc. engages in the development and commercialization of gastrointestinal products for companion and production animals. Its product, Canalevia, is the company's prescription drug product candidate for the treatment of various forms diarrhea in dogs. It also developed its non-prescription product, Neonorm Calf, which helps dairies and beef farms proactively retain fluid in calves. The company was founded by Lisa A. Conte on June 6, 2013 and is headquartered in San Francisco, CA.

Description

Jaguar Animal Health, Inc., an animal health company, focuses on developing and commercializing gastrointestinal products for companion and production animals, foals, and high value horses. The company's lead prescription drug product candidate includes Canalevia, a canine-specific formulation of Crofelemer for the treatment of chemotherapy-induced diarrhea and acute watery diarrhea in dogs. It is also developing Crofelemer to treat acute colitis in horses and acute watery diarrhea in cats; Neonorm, an enteric-coated tablet for scours in preweaned dairy calves, as well as other animal species, such as horses, goats, and sheep; and other product candidates, including Virend for feline herpes and NP-500 for Type II diabetes and metabolic syndrome. The company was founded in 2013 and is headquartered in San Francisco, California.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading